BrightGene is a biopharma company.
Business Model:
Revenue: $58.2M
Employees: 0-0
Address: No.218Xinghu Road, SIP
City: Suzhou
State: jiangsu province
Zip: 215000
Country: CN
BrightGene Bio-medical technology Co.,Ltd., is a leading Chinese biopharmaceutical company in small molecules and nucleotide drugs areas. Advised by China-based venture capital fund Laurel Venture Capital, BrightGene invests in all stage therapeutics and innovations.
Contact Phone:
Contact Email:
Listed Exchange:
SSE
IPO Date:
11/8/2019
Ticker Symbol:
688166
IPO Price:
$1.816804368335287/share
Amount Raised:
$74M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
7/2020 | Citryll | Series B | 0 |
7/2019 | Citryll | Series A | - |
8/2018 | DNALite Therapeutics | Seed Round | 0 |
7/2020 | Citryll | Series B | 0 |
7/2019 | Citryll | Series A | - |
8/2018 | DNALite Therapeutics | Seed Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|